المؤلفون: Gaiffe, Emilie, Vernerey, Dewi, Bardiaux, Laurent, Leroux, Franck, Meurisse, Aurelia, Bamoulid, Jamal, Courivaud, Cécile, Saas, Philippe, Tiberghien, Pierre, Ducloux, Didier

المصدر: Frontiers in Immunology; 5/31/2022, Vol. 13, p1-12, 12p

مصطلحات موضوعية: RED blood cell transfusion, KIDNEY transplantation, TRANSPLANTATION of organs, tissues, etc., ERYTHROCYTES

مستخلص: Background: Red blood cell (RBC) transfusions are frequently required in the early period after kidney transplantation. However, the consequences of RBC transfusions on long-term outcomes are largely unrecognized. Methods: We conducted a nationwide French cohort study involving all 31 French kidney transplant centers. Patients having received a first kidney transplant between January 1, 2002 and December 31, 2008 were identified through the national registry of the French BioMedecine Agency (Agence de BioMédecine). Number and date of RBC transfusions were collected from the national database of the French transfusion public service. The primary endpoint was transplant failure defined as graft loss or death with a functional graft. Results: Among 12,559 patients included during the study period, 3,483 (28%) were transfused during the first 14 days post-transplant. Median follow-up was 7.6 (7.5-7.8) years. Multivariable analysis determined that post-transplant RBC transfusion was associated with an increased risk in transplant failure (HR 1.650, 95%CI [1.538;1.771] p<0.0001). Both sensitivity and propension score analyses confirmed the previous result. Conclusions: Early red blood cell transfusion after kidney transplantation is associated with increased transplant failure. [ABSTRACT FROM AUTHOR]

: Copyright of Frontiers in Immunology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Gaiffe, Emilie, Vernerey, Dewi, Bardiaux, Laurent, Leroux, Franck, Meurisse, Aurelia, Bamoulid, Jamal, Courivaud, Cecile, Saas, Philippe, Hazzan, Marc, Tiberghien, Pierre, Ducloux, Didier

المصدر: JAMA Network Open; 9/14/2023, Vol. 6 Issue 9, pe2332821-e2332821, 1p

المؤلفون: Seigeot, Audrey, Desmarets, Maxime, Rumpler, Anne, Leroux, Franck, Deconinck, Eric, Monnet, Elisabeth, Bardiaux, Laurent

المصدر: Transfusion; Jun2018, Vol. 58 Issue 6, p1377-1387, 11p, 1 Diagram, 5 Charts

مصطلحات موضوعية: BLOOD platelet transfusion, THROMBOCYTOPENIA, HEMATOLOGIC malignancies, HEMATOLOGY, BLOOD coagulation disorders, BLOOD collection, BLOOD cell count, ABO blood group system, BLOOD irradiation, CLINICAL trials, PREVENTIVE medicine, MULTIVARIATE analysis, TREATMENT effectiveness, BLOOD grouping & crossmatching, PLATELET-rich plasma, THERAPEUTICS

مستخلص: Background: A better knowledge of the connections between platelet concentrate (PC) characteristics and transfusion outcomes in day-to-day practice would help improve the selection process of the most appropriate PC.Study Design and Methods: In this study of prophylactic platelet transfusions in patients with hematologic malignancies between 2002 and 2012, outcome criteria were corrected count increments (CCIs) and platelet transfusion intervals (TIs, in days). Studied characteristics were ABO matching status, platelet source, dose, storage duration, irradiation, washing, and transfusion sequence number (TSN). The analysis consisted of multivariable linear mixed-effects models with adjustments for patient diagnosis, sex, and type of treatment.Results: Overall, 869 patients and 6662 platelet transfusions were analyzed. For each day after the second day of storage, the CCI and TI decreased by 0.88 and 0.06 day, respectively. Compared to ABO-identical, transfusion with major ABO-incompatible PCs decreased the CCI and TI by 0.79 and 0.21 day, respectively. Platelet washing reduced the CCI and TI by 2.28 and 0.24 day, respectively. There was no significant association between platelet source or irradiation and CCI or TI. TI increased as the platelet dose per kg increased. Both CCI and TI decreased as the TSN increased.Conclusion: Transfusion outcomes were significantly related to several PC-related factors. Associations for ABO matching status and storage duration were stronger than previously reported. Taking into account such factors when selecting a PC for transfusion could be beneficial to the recipient. [ABSTRACT FROM AUTHOR]

: Copyright of Transfusion is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Gamonet, Clémentine, Mourey, Guillaume, Aupet, Sophie, Biichle, Sabéha, Petitjean, Régis, Vidal, Chrystelle, Pugin, Aurore, Naegelen, Christian, Tiberghien, Pierre, Morel, Pascal, Angelot‐Delettre, Fanny, Seilles, Estelle, Saas, Philippe, Bardiaux, Laurent, Garnache‐Ottou, Francine

المصدر: Transfusion; Mar2017, Vol. 57 Issue 3, p504-516, 13p

مصطلحات موضوعية: ERYTHROCYTES, BLOOD transfusion, FLOW cytometry, LEUCOCYTES, CLINICAL trials, BLOOD collection, CELL membranes, CRYOPRESERVATION of organs, tissues, etc., TIME

مستخلص: Background: The procoagulant and proinflammatory microparticles (MPs) released during storage of packed red blood cells (pRBCs) can potentially modify transfusion benefits. A robust method to quantify MPs in pRBCs is needed to evaluate their impact in clinical trials.Study Design and Methods: The objective was to validate the preanalytic conditions required to prepare pRBC supernatant as well as a method to quantify and evaluate MP variations over 42 days of pRBC storage.A flow cytometry method with size-calibrated beads was developed and fully validated. Quantification of MPs in pRBCs (n = 109) was assessed during short-term (7 days) and long-term (42 days) storage at 4°C, during short-term storage (8 hours) at room temperature, and after 2 years frozen.Results: Repeatability, reproducibility, and linearity of the quantification method were validated, and variations during conservation are presented. There was high variability in RBC (erythrocyte) MP (ERMP) and platelet MP (PMP) levels between RBC units, depending on the filter used for leukocyte reduction. During the 42 days of storage at 4°C, significant increases in ERMPs and PMPs occurred (from 58 to 138 ERMPs/µL from Day 2 to Day 42; p = 0.0002; and from 326 to 771 PMPs/µL from Day 2 to Day 42; p = 0.00026).Conclusion: We use a robust method to confirm that ERMPs and PMPs are present to various degrees in pRBCs and that storage for 42 days significantly increases their generation. This method is robust enough to allow MP quantification in pRBCs and is adapted to evaluate the clinical impact of transfused MPs in prospective clinical trials. [ABSTRACT FROM AUTHOR]

: Copyright of Transfusion is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Lhomme, Sebastien^1,2,3, Bardiaux, Laurent⁴, Abravanel, Florence^1,2,3, Gallian, Pierre^5,6, Kamar, Nassim^1,3,7, Izopet, Jacques^1,2,3 izopet.j@chu-toulouse.fr

المصدر: Emerging Infectious Diseases. Feb2017, Vol. 23 Issue 2, p353-356. 4p. 1 Diagram.

مصطلحات موضوعية: *HEPATITIS E virus, *VIRUS diseases, *TRANSPLANTATION of organs, tissues, etc., *PATIENTS, *DISEASE risk factors

مستخلص: The rate of transfusion-transmitted hepatitis E virus (HEV) in transplant recipients is unknown. We identified 60 HEV-positive solid organ transplant patients and retrospectively assessed their blood transfusions for HEV. Seven of 60 patients received transfusions; 3 received HEV-positive blood products. Transfusion is not the major route of infection in this population. [ABSTRACT FROM AUTHOR]

المؤلفون: Desmarets, Maxime¹, Bardiaux, Laurent², Benzenine, Eric³, Dussaucy, Alain⁴, Binda, Delphine¹, Tiberghien, Pierre⁵, Quantin, Catherine^3,6,7, Monnet, Elisabeth^1,8

المصدر: Transfusion. May2016, Vol. 56 Issue 5, p1213-1222. 10p.

مصطلحات موضوعية: *RED blood cell transfusion, *BLOOD collection, *BLOOD donors, *BLOOD transfusion, *COMPARATIVE studies, *GRAFT versus host reaction, *CARDIAC surgery, *RESEARCH methodology, *MEDICAL cooperation, *RESEARCH, *SEX distribution, *SURVIVAL analysis (Biometry), *TIME, *EVALUATION research, *RETROSPECTIVE studies, CARDIAC surgery patients

مصطلحات جغرافية: FRANCE

مستخلص: Background: Red blood cell (RBC) storage lesions and RBCs from females transfused into male recipients may have adverse effects on transfusion recipients' survival. We hypothesized that the effect of donor sex and the effect of age of blood on mortality would be most apparent in cardiac surgery patients.Study Design and Methods: Using data from French Blood Services and two university hospitals, we conducted a retrospective cohort study on cardiac surgery patients whose first transfusion occurred between 2007 and 2011. The age of blood and donor sex effects on 1-year survival were studied using Cox regression modeling, with time-dependent stratification on the number of RBCs and adjustments for the type of surgery and other products transfused.Results: Among the 2715 cardiac surgery patients, 85.1% were alive after 1 year. Age of blood and donor sex were associated with survival before adjustments (p < 0.0001). However, the adjusted hazard ratios (HRs) for patients transfused with blood stored for 29 days or more versus 14 days or less were 0.97 (95% confidence interval [95% CI], 0.69-1.35; p = 0.98) and 1.22 (95% CI, 0.81-1.82) for patients who received only sex-mismatched RBCs versus all matched units (p = 0.27). For males transfused solely with female RBCs, the HR was 0.96 (95% CI, 0.57-1.61; p = 0.69); in females transfused only with male RBCs, it was 2.03 (95% CI, 0.87-4.73; p = 0.17).Conclusions: In this first study of survival after transfusion in France, there was no significant effect for age of blood or donor sex. Contrary to previously reported data, female RBCs appear to be safe for male recipients. [ABSTRACT FROM AUTHOR]

المؤلفون: Bartelmaos, Tonine, Chabanel, Anne, Léger, Julie, Villalon, Loïc, Gillon, Marie Christine, Rouget, Claude, Gomola, Alexandra, Denninger, Marie Hélène, Tardivel, René, Naegelen, Christian, Courtois, Françoise, Bardiaux, Laurent, Giraudeau, Bruno, Ozier, Yves

المصدر: Transfusion; Jun2013, Vol. 53 Issue 6, p1335-1345, 11p, 1 Diagram, 9 Charts

مصطلحات موضوعية: BLOOD transfusion, BLOOD plasma, LIVER transplantation, COMPARATIVE studies, BLOOD loss estimation, CLINICAL trials

مستخلص: BACKGROUND: The clinical equivalence of plasma treated to reduce pathogen transmission and untreated plasma has not been extensively studied. A clinical trial was conducted in liver transplant recipients to compare the efficacy of three plasmas. STUDY DESIGN AND METHODS: A randomized, equivalence, blinded trial was performed in four French liver transplantation centers. The three studied (fresh-frozen) plasmas were quarantine (Q-FFP), methylene blue (MB-FFP), and solvent/detergent (S/D-FFP) plasmas. The primary outcome was the volume of plasma transfused during transplantation. Secondary outcomes included intraoperative blood loss, hemostasis variables corrections, and adverse events. RESULTS: One-hundred patients were randomly assigned in the MB-FFP, 96 in the S/D-FFP, and 97 in the Q-FFP groups, respectively. The median volumes of plasma transfused were 2254, 1905, and 1798 mL with MB-FFP, S/D-FFP, and Q-FFP, respectively. The three plasmas were not equivalent. MB-FFP was not equivalent to the two other plasmas, but S/D-FFP and Q-FFP were equivalent. The median numbers of transfused plasma units were 10, 10, and 8 units with MB-FFP, S/D-FFP, and Q-FFP, respectively. Adjustment on bleeding risk factors diminished the difference between groups: the excess plasma volume transfused with MB-FFP compared to Q-FFP was reduced from 24% to 14%. Blood loss and coagulation factors corrections were not significantly different between the three arms. CONCLUSION: Compared to both Q-FFP and S/D-FFP, use of MB-FFP was associated with a moderate increase in volume transfused, partly explained by a difference in unit volume and bleeding risk factors. Q-FFP was associated with fewer units transfused than either S/D-FFP or MB-FFP. [ABSTRACT FROM AUTHOR]

: Copyright of Transfusion is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Peyrard, Thierry, Bardiaux, Laurent, Krause, Claire, Kobari, Ladan, Lapillonne, Hélène, Andreu, Georges, Douay, Luc

المصدر: Transfusion Medicine Reviews; Jul2011, Vol. 25 Issue 3, p206-216, 11p

مستخلص: The transfusion of red blood cells (RBCs) is now considered a well-settled and essential therapy. However, some difficulties and constraints still occur, such as long-term blood product shortage, blood donor population aging, known and yet unknown transfusion-transmitted infectious agents, growing cost of the transfusion supply chain management, and the inescapable blood group polymorphism barrier. Red blood cells can be now cultured in vitro from human hematopoietic, human embryonic, or human-induced pluripotent stem cells (hiPSCs). The highly promising hiPSC technology represents a potentially unlimited source of RBCs and opens the door to the revolutionary development of a new generation of allogeneic transfusion products. Assuming that in vitro large-scale cultured RBC production efficiently operates in the near future, we draw here some futuristic but realistic scenarios regarding potential applications for alloimmunized patients and those with a rare blood group. We retrospectively studied a cohort of 16,486 consecutive alloimmunized patients (10-year period), showing 1 to 7 alloantibodies with 361 different antibody combinations. We showed that only 3 hiPSC clones would be sufficient to match more than 99% of the 16,486 patients in need of RBC transfusions. The study of the French National Registry of People with a Rare Blood Phenotype/Genotype (10-year period) shows that 15 hiPSC clones would cover 100% of the needs in patients of white ancestry. In addition, one single hiPSC clone would meet 73% of the needs in alloimmunized patients with sickle cell disease for whom rare cryopreserved RBC units were required. As a result, we consider that a very limited number of RBC clones would be able to not only provide for the need for most alloimmunized patients and those with a rare blood group but also efficiently allow for a policy for alloimmunization prevention in multiply transfused patients. [Copyright &y& Elsevier]

: Copyright of Transfusion Medicine Reviews is the property of W B Saunders and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Comont, Thibault^1,2, Tavitian, Suzanne³, Bardiaux, Laurent⁴, Fort, Marylise⁵, Debiol, Bénédicte⁴, Morère, Danièle⁴, Bérard, Emilie^6,7, Delabesse, Eric^2,8,9, Luquet, Isabelle^2,8,9, Martinez, Salima¹⁰, Huguet, Françoise³, Récher, Christian^2,3,9 recher.christian@iuct-oncopole.fr, Bertoli, Sarah^2,3,9

المصدر: Leukemia Research. Oct2017, Vol. 61, p62-67. 6p.

مصطلحات موضوعية: *BLOOD platelet transfusion, *MYELOID leukemia, *CANCER chemotherapy, *LEUCOCYTES, *THROMBOCYTOPENIA, *THROMBOPOIETIN receptors

مستخلص: Platelet transfusion refractoriness (PTR) is a major adverse event in the management of acute myeloid leukemia (AML). In a series of 897 adult patients with AML receiving intensive chemotherapy, we identified 41 patients (4.8%) with PTR. PTR was more frequently observed in parous women, patients with extra-medullary disease, a low white blood cell count, an infection, or hemophagocytic syndrome. Among the 31 patients with anti-human leucocyte antigen (HLA) antibodies, an HLA-matched donor was identified for 18 patients (58.1%). Median time between diagnosis of PTR and the first HLA-matched transfusion was 12.5 days. HLA-matched transfusions induced a significant increment in platelet counts in 37% of cases. Thrombopoietin receptor agonists were given to 10 patients but did not shorten the duration of thrombocytopenia, reduce severe bleeding, or early death. Grade 3 − 4 bleeding events during induction, early death caused by bleeding, and death caused by bleeding at any time were significantly greater in patients that had platelet transfusion refractoriness (22% vs . 4.1%, P < 0.0001; 12.2% vs . 1.4%, P = 0.0006; and 24.4% vs . 5.3%, P < 0.0001; respectively). PTR during chemotherapy for AML significantly increased the risk of early and late deaths caused by a severe bleeding event. Improved understanding of platelet destruction is needed to design mechanism-based therapeutic strategies. [ABSTRACT FROM AUTHOR]

المؤلفون: Ribou, Ghislaine¹ gribou@ch-aix.fr, Migot, Corinne², Bardiaux, Laurent³, Tessier, Pascal²

المصدر: Transfusion Clinique et Biologique. Nov2016, Vol. 23 Issue 4, p267-267. 1p.

مستخلص: La nouvelle organisation de l’identitovigilance à l’EFS PYMED est basée sur la création d’un poste de correspondant d’identitovigilance régional. L’identitovigilance devient un processus à part entière, qui s’intègre dans le processus de l’amélioration de la qualité. La possibilité de déclarer des incidents d’identitovigilance, de les traiter, de proposer des actions correctives a été un plus. Le réseau en région facilite la connaissance des pratiques, permet de les faire évoluer et de les améliorer. En 2014, nous avons travaillé, dans le cadre d’un DPC d’identitovigilance, à la création d’un réseau régional fédérant des personnes de sites et de métiers différents, touchant au périmètre des donneurs de sang ou bien de patients : médecins, pharmaciens, techniciens. Ce DPC a consisté en l’analyse de l’existant, l’analyse d’un effet indésirable transfusionnel, et en la proposition d’indicateur. L’intégration progressive des donneurs des différentes régions dans la base nationale a fait apparaître un nombre considérable de doublons à fusionner, en toute sécurité. Une quantité importante de doublons a été gérée en régional. Grâce à un outil informatique performant permettant la détection d’anomalies telles que les doublons, les personnes sensibilisées du réseau ont permis d’harmoniser les pratiques et d’évaluer le travail accompli. Cet outil informatique appelé le portail des surveillances a été amélioré au fur et à mesure de la gestion des anomalies par les utilisateurs. Mon travail a permis de fédérer ce réseau, avec un accompagnement important dans la formation de ce nouvel outil et en identitovigilance en région. Conclusion la gestion de l’identitovigilance en région PYMED a été favorisée par la mise en place d’un réseau de correspondants locaux dans tous les sites de la région. Ceci a permis d’améliorer les pratiques. Les différents acteurs du réseau se sont approprié progressivement la gestion des anomalies. [ABSTRACT FROM AUTHOR]